{"entity":{"id":"cemiplimab-nut","kind":"trial","name":"Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)","aka":[],"tldr":"The first dedicated immunotherapy trial in NUT carcinoma, asking whether a PD-1 antibody can do anything in a cancer that chemotherapy rarely controls.","summary":"Case reports have described occasional responses of NUT carcinoma to checkpoint inhibitors despite its low mutation burden. This Northwestern University pilot gives cemiplimab to fifteen patients with metastatic or unresectable disease and measures safety and clinical activity. It is recruiting.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07050186","url":"https://clinicaltrials.gov/study/NCT07050186"}],"tags":["owner-request"],"related":[],"cancers":["nut-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07050186","phase":"2","setting":"Incurable metastatic or unresectable NUT carcinoma: single-arm open-label pilot of the PD-1 antibody cemiplimab; started August 2025, 15 planned","sponsor":"Northwestern University","enrolled":15,"outcomes":[]},"route":"/trials/cemiplimab-nut/","neighbours":{"cancer":[{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}]}}